US 11,866,444 B2
Oxabicycloheptane prodrugs
John S. Kovach, Pasadena, CA (US); Robert A. Volkmann, Groton, CT (US); and Anthony Marfat, Groton, CT (US)
Assigned to Lixte Biotechnology, Inc., Pasadena, CA (US)
Filed by Lixte Biotechnology, Inc., Pasadena, CA (US)
Filed on Jan. 27, 2022, as Appl. No. 17/586,548.
Application 15/968,462 is a division of application No. 15/154,304, filed on May 13, 2016, granted, now 9,988,394, issued on Jun. 5, 2018.
Application 17/586,548 is a continuation of application No. 16/782,970, filed on Feb. 5, 2020, granted, now 11,236,102, issued on Feb. 1, 2022.
Application 16/782,970 is a continuation of application No. 16/439,227, filed on Jun. 12, 2019, granted, now 10,618,908, issued on Apr. 14, 2020.
Application 16/439,227 is a continuation of application No. 15/968,462, filed on May 1, 2018, granted, now 10,364,252, issued on Jul. 30, 2019.
Claims priority of provisional application 62/162,501, filed on May 15, 2015.
Prior Publication US 2022/0235066 A1, Jul. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 493/08 (2006.01); A61K 31/337 (2006.01); A61K 31/496 (2006.01); C07D 493/22 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 45/06 (2006.01); A61K 31/34 (2006.01); A61P 35/00 (2006.01)
CPC C07D 493/08 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/337 (2013.01); A61K 31/34 (2013.01); A61K 31/496 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61P 35/00 (2018.01); C07D 493/22 (2013.01)] 10 Claims
 
1. A method for in vivo delivery of endothall to a cancer cell in a subject afflicted with cancer, the method comprising administering to the subject a compound having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein the delivery of endothall to the cancer cell in the subject is effective to treat the cancer, and
wherein the cancer is brain cancer, breast cancer, colon cancer, large cell lung cancer, adenocarcinoma of the lung, small cell lung cancer, stomach cancer, liver cancer, ovary adenocarcinoma, pancreas carcinoma, prostate carcinoma, promylocytic leukemia, chronic myelocytic leukemia, acute lymphocytic leukemia, colorectal cancer, ovarian cancer, lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma cell, adrenocortical cancer, bladder cancer, osteosarcoma, cervical cancer, esophageal, gallbladder, head and neck cancer, renal cancer, melanoma, pancreatic cancer, rectal cancer, thyroid cancer, throat cancer, prostate cancer, lung cancer, or hepatocellular carcinoma.